To validate the therapeutic mechanism of BF in EGFR-driven HCC, we evaluated its impact on RAS/RAF/MEK/ERK signaling using EGFR-overexpressing HepG2 and HCCLM3 cell models. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.